• 219articles
    Sort by
    Latested
    Open Access
    Review
    Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy
    Innate lymphoid cells (ILCs) are the most recently discovered class of innate immune cells found to have prominent roles in various human immune-related pathologies such as infection and autoimmune ...
    James Michael Verner ... Eric Jou
    Published: April 23, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00219
    Viewed:34
    Downloaded:6
    Open Access
    Original Article
    Hexachlorobenzene as a differential modulator of the conventional and metronomic chemotherapy response in triple negative breast cancer cells
    Aim: Triple negative breast cancer (TNBC) is usually treated with high doses of paclitaxel, whose effectiveness may be modulated by the action of environmental contaminants such as hexachlorobenz...
    Yamila Sanchez ... Alejandro Español
    Published: March 21, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00218
    Viewed:278
    Downloaded:14
    Open Access
    Review
    Improving the quality of patient care in lung cancer: key factors for successful multidisciplinary team working
    International Guidelines as well as Cancer Associations recommend a multidisciplinary approach to lung cancer care. A multidisciplinary team (MDT) can significantly improve treatment decision-making...
    Alessandro Morabito ... Giacomo Pascarella
    Published: March 21, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00217
    Viewed:261
    Downloaded:15
    Open Access
    Mini Review
    Potential of targeting signal-transducing adaptor protein-2 in cancer therapeutic applications
    Adaptor proteins play essential roles in various intracellular signaling pathways. Signal-transducing adaptor protein-2 (STAP-2) is an adaptor protein that possesses pleckstrin homology (PH) and Src...
    Taiga Maemoto ... Tadashi Matsuda
    Published: March 07, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00216
    Viewed:288
    Downloaded:15
    Open Access
    Review
    Novel therapeutic strategies targeting myeloid-derived suppressor cell immunosuppressive mechanisms for cancer treatment
    Cancer is the leading cause of death globally superseded only by cardiovascular diseases, and novel strategies to overcome therapeutic resistance against existing cancer treatments are urgently requ...
    Eric Jou ... Fizza Nasim
    Published: February 28, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00212
    Viewed:728
    Downloaded:13
    Open Access
    Review
    Conceptual breakthroughs of the long noncoding RNA functional system and its endogenous regulatory role in the cancerous regime
    Long noncoding RNAs (lncRNAs) derived from noncoding regions in the human genome were once regarded as junks with no biological significance, but recent studies have shown that these molecules are h...
    Anyou Wang
    Published: February 27, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00211
    Viewed:423
    Downloaded:13
    Open Access
    Review
    Recent preclinical and clinical advances in radioimmunotherapy for non-Hodgkin’s lymphoma
    Radioimmunotherapy (RIT) is a therapy that combines a radioactive nucleotide with a monoclonal antibody (mAb). RIT enhances the therapeutic effect of mAb and reduces toxicity compared with conventio...
    Hiroki Goto ... Seiji Okada
    Published: February 28, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00213
    Viewed:506
    Downloaded:26
    Open Access
    Case Report
    A case of immunotherapy-induced thyroiditis
    Immunotherapy treatments for cancer are known to cause adverse thyroid events which present a diagnostic challenge to clinicians and radiologists. This case report highlights the importance of a hig...
    George Pears ... Joseph Sacco
    Published: February 28, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00214
    Viewed:444
    Downloaded:21
    Open Access
    Review
    Early-stage triple negative breast cancer: the therapeutic role of immunotherapy and the prognostic value of pathological complete response
    Triple negative breast cancer (TNBC) represents an aggressive disease associated with a high risk of recurrence after curative treatment and a poor prognosis in the metastatic setting. Chemotherapy ...
    Pierluigi De Santis ... Palma Fedele
    Published: February 28, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00215
    Viewed:649
    Downloaded:26
    Open Access
    Review
    Exploring monocarboxylate transporter inhibition for cancer treatment
    Cells are separated from the environment by a lipid bilayer membrane that is relatively impermeable to solutes. The transport of ions and small molecules across this membrane is an essential process...
    Tomas Koltai, Larry Fliegel
    Published: February 23, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00210
    Viewed:389
    Downloaded:21
    Open Access
    Review
    The oncogenic role of hepatitis B virus X gene in hepatocarcinogenesis: recent updates
    Hepatocellular carcinoma (HCC) is the most prevalent form of primary liver cancers with high mortality rate. Among its various etiological factors, one of the major risk factors for HCC is a chronic...
    Agustiningsih Agustiningsih ... Caecilia Sukowati
    Published: February 20, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00209
    Viewed:485
    Downloaded:22
    Open Access
    Original Article
    Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells
    Aim: Triple-negative breast cancer (TNBC) is a very aggressive subset of breast cancer, with limited treatment options, due to the lack of three commonly targeted receptors, which merits the need...
    Praveen Sahu ... Raji Sundararajan
    Published: February 19, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00204
    Viewed:404
    Downloaded:11
    Open Access
    Original Article
    Quantitative peritumoral magnetic resonance imaging fingerprinting improves machine learning-based prediction of overall survival in colorectal cancer
    Aim: To investigate magnetic resonance imaging (MRI)-based peritumoral texture features as prognostic indicators of survival in patients with colorectal liver metastasis (CRLM). Methods: Fr...
    Azadeh Tabari ... Dania Daye
    Published: February 19, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00205
    Viewed:405
    Downloaded:16
    Open Access
    Mini Review
    Management of stage III non-small-cell lung cancer: rays of hope
    Lung cancer remains the most common cause of cancer death across the world. Non-small-cell lung cancer (NSCLC) represents the most frequent type of lung cancer and is frequently diagnosed at an adva...
    Floryane Kim ... Alex Friedlaender
    Published: February 19, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00206
    Viewed:484
    Downloaded:27
    Open Access
    Review
    CD99 tumor associated antigen is a potential target for antibody therapy of T-cell acute lymphoblastic leukemia
    Monoclonal antibodies (mAbs) are an effective drug for targeted immunotherapy in several cancer types. However, so far, no antibody has been successfully developed for certain types of cancer, inclu...
    Kamonporn Kotemul ... Nuchjira Takheaw
    Published: February 19, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00207
    Viewed:482
    Downloaded:14
    Open Access
    Mini Review
    Exploring the function of myeloid cells in promoting metastasis in head and neck cancer
    Head and neck cancer (HNC) is a challenging disease that lacks effective treatment, particularly in the cases that spread locoregionally and metastasize distantly, dramatically reducing patient surv...
    Dakota Dike Dimegwu Okwuone ... Gregory N. Gan
    Published: February 19, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00208
    Viewed:1103
    Downloaded:21
    Open Access
    Review
    DNA methylation modulates epigenetic regulation in colorectal cancer diagnosis, prognosis and precision medicine
    Colorectal cancer (CRC) is a multifaceted disease influenced by the interplay of genetic and environmental factors. The clinical heterogeneity of CRC cannot be attributed exclusively to genetic dive...
    Jingxin Ye ... Weifeng Ding
    Published: January 28, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00203
    Viewed:613
    Downloaded:29
    Open Access
    Review
    Role of STAT3 in pancreatic cancer
    Pancreatic cancer remains a serious and deadly disease, impacting people globally. There remain prominent gaps in the current understanding of the disease, specifically regarding the role of the sig...
    Zachary Hamel ... Shrikant Anant
    Published: January 17, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00202
    Viewed:561
    Downloaded:23
    Open Access
    Original Article
    Identification of lysyl oxidase as an adipocyte-secreted mediator that promotes a partial mesenchymal-to-epithelial transition in MDA-MB-231 cells
    Aim: Breast cancer (BC) is the most common cancer in women worldwide, where adiposity has been linked to BC morbidity. In general, obese premenopausal women diagnosed with triple-negative BC (TNB...
    Cassidy M. Van Stiphout ... Alicia M. Viloria-Petit
    Published: January 16, 2024 Explor Target Antitumor Ther. DOI: 10.37349/etat.2024.00201
    Viewed:614
    Downloaded:20
    Open Access
    Original Article
    Cola rostrata K. Schum. constituents induce cytotoxicity through reactive oxygen species generation and mitochondrial membrane depolarisation
    Aim: While the traditional use of Cola rostrata in treating illnesses and diseases has not been reported, the presence of cytotoxic principles has been reported in phylogenetically and biogeograp...
    Babatunde E. Ajayi ... Amos A. Fatokun
    Published: December 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00200
    Viewed:580
    Downloaded:13
    Open Access
    Perspective
    Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline BRCA mutation?
    Pembrolizumab combined with chemotherapy has been established as the preferred first-line therapy for treating metastatic triple-negative breast cancer (mTNBC) with programmed cell death ligand-1 (P...
    Sabah Alaklabi ... Shipra Gandhi
    Published: December 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00198
    Viewed:503
    Downloaded:12
    Open Access
    Review
    Therapeutic significance of tumor microenvironment in cholangiocarcinoma: focus on tumor-infiltrating T lymphocytes
    Cholangiocarcinoma (CCA) is a highly aggressive type of adenocarcinoma distinguished by its invasiveness. Depending on specific anatomical positioning within the biliary tree, CCA can be categorized...
    Chaoqun Li ... Jieer Ying
    Published: December 28, 2023 Explor Target Antitumor Ther DOI: 10.37349/etat.2023.00199
    Viewed:632
    Downloaded:9
    Open Access
    Review
    Telehealth in breast cancer following the coronavirus disease 2019 pandemic
    Breast cancer (BC) is the second most diagnosed cancer in 2018 with around 2.3 million cases globally in 2020. In March 2020 and after its worldwide spread, the World Health Organization (WHO) decla...
    Jean Zeghondy ... Barbara Pistilli
    Published: December 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00195
    Viewed:416
    Downloaded:9
    Open Access
    Review
    Post-translational modulation of cell signalling through protein succinylation
    Cells need to adapt their activities to extra- and intracellular signalling cues. To translate a received extracellular signal, cells have specific receptors that transmit the signal to downstream p...
    Katharina F. Kubatzky ... Dayoung Yu
    Published: December 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00196
    Viewed:847
    Downloaded:33
    Open Access
    Review
    Current implications and challenges of artificial intelligence technologies in therapeutic intervention of colorectal cancer
    Irrespective of men and women, colorectal cancer (CRC), is the third most common cancer in the population with more than 1.85 million cases annually. Fewer than 20% of patients only survive beyond f...
    Kriti Das ... Chakresh Kumar Jain
    Published: December 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00197
    Viewed:608
    Downloaded:19
    Open Access
    Review
    Recent advancements in targeted protein knockdown technologies—emerging paradigms for targeted therapy
    A generalized therapeutic strategy for various disease conditions, including cancer, is to deplete or inactivate harmful protein targets. Various forms of protein or gene silencing molecules, e.g., ...
    Mansi Joshi ... Abhijit De
    Published: December 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00194
    Viewed:843
    Downloaded:38
    Open Access
    Original Article
    Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer
    Aim: It is important to identify anti-cancer compounds that can inhibit specific molecular targets to eradicate androgen-receptor negative (ARneg), androgen-independent (AI) prostate cancer, whic...
    Vignesh Sivaganesh, Bela Peethambaran
    Published: December 20, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00192
    Viewed:624
    Downloaded:13
    Open Access
    Original Article
    Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing tumour protein 53 gene status
    Aim: In response to DNA damage the serine/threonine-specific protein kinase checkpoint kinase 1 (CHK1) is activated allowing cells to enter S phase (S) and G2 phase (G2) cell-cycle arrest. CHK1 i...
    Ali JN Duabil ... George DD Jones
    Published: December 21, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00193
    Viewed:656
    Downloaded:16
    Open Access
    Case Report
    Is oligoprogression a potentially curable disease in epidermal growth factor receptor mutant lung adenocarcinoma?
    Third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have shown impressive results in EGFR mutant lung cancer (LC) patients in terms of disease control rate wit...
    Sviatoslav Chekhun ... Maria Saigí
    Published: December 13, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00191
    Viewed:964
    Downloaded:15
    Open Access
    Review
    Targeting cancer stem cell plasticity in triple-negative breast cancer
    Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer subtype with limited treatment options. Cancer stem cells (CSCs) are thought to play a crucial role in TNBC progression and ...
    Zhengwang Guo, Shuyan Han
    Published: December 11, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00190
    Viewed:471
    Downloaded:12
    Open Access
    Original Article
    Chimeric single-chain variable fragment-human immunoglobulin G crystallizable fragment antibody against GD2 for neuroblastoma targeted immunotherapy
    Aim: The present study aims to generate chimeric mouse single-chain variable fragment (scFv) and immunoglobulin G1 (IgG1) crystallizable fragment (Fc) antibody against disialoganglioside (GD2) fo...
    Witida Laopajon ... Watchara Kasinrerk
    Published: December 06, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00188
    Viewed:802
    Downloaded:20
    Open Access
    Case Report
    Unexpected “Lazarus response” to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer
    Early clinical trials aimed to halt cancer progression by inhibiting the growth of new blood vessels in tumors through single-agent targeted therapy with bevacizumab. These trials largely proved uns...
    Alexey V. Emshanov ... Evgeny N. Imyanitov
    Published: December 06, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00189
    Viewed:484
    Downloaded:17
    Open Access
    Meta-Analysis
    Comparing efficacy and safety of upfront treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a network meta-analysis
    Aim: This article is based on our previous research, which was presented as a post at the Congress Aiom 2022 Congress and published in Tumori Journal as Conference Abstract (Tumori J. 2022;108:1...
    Marco Filetti ... Gennaro Daniele
    Published: December 01, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00187
    Viewed:650
    Downloaded:28
    Open Access
    Commentary
    A decade of CD4+ chimeric antigen receptor T-cell evolution in two chronic lymphocytic leukemia patients: were chronic lymphocytic leukemia cells present?
    On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin...
    Dimitrios Bouzianas, Stella Bouziana
    Published: October 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00186
    Viewed:752
    Downloaded:18
    Open Access
    Review
    Overcoming phenotypic switching: targeting protein-protein interactions in cancer
    Alternative protein-protein interactions (PPIs) arising from mutations or post-translational modifications (PTMs), termed phenotypic switching (PS), are critical for the transmission of alternative ...
    Christos Ladias ... Nikolaos A. Papanikolaou
    Published: October 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00181
    Viewed:538
    Downloaded:15
    Open Access
    Review
    Coronavirus disease 2019 and lung cancer: where are we?
    Oncology patients are more susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection due to hospital contact and an immunological system that can be compromised by antine...
    Abrahams Ocanto ... Felipe Couñago
    Published: October 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00182
    Viewed:712
    Downloaded:10
    Open Access
    Systematic Review
    Impact of coronavirus disease 2019 pandemic on good clinical practice trials in oncology
    Aim: Coronavirus disease 2019 (COVID-19) became pandemic on 11th March 2020 and it deeply stressed the healthcare system. Cancer patients represent a vulnerable population, so many recommendation...
    Veronica Agostinelli ... Rossana Berardi
    Published: October 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00183
    Viewed:587
    Downloaded:7
    Open Access
    Original Article
    Acryl-3,5-bis(2,4-difluorobenzylidene)-4-piperidone targeting cellular JUN proto-oncogene, AP-1 transcription factor subunit inhibits head and neck squamous cell carcinoma progression
    Aim: Head and neck squamous cell carcinoma (HNSCC) is the seventh most common cancer worldwide with a survival rate below fifty percent. Addressing meager therapeutic options, a series of small m...
    Levi Arnold ... Sufi Mary Thomas
    Published: October 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00184
    Viewed:1197
    Downloaded:84
    Open Access
    Perspective
    Cholesterol esterification and p53-mediated tumor suppression
    Many human cancers carry missense mutations in or deletions of the tumor protein 53 (TP53) tumor suppressor gene. TP53’s product, p53 regulates many biological processes, including cell metabolism...
    Youjun Li ... Edward V. Prochownik
    Published: October 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00185
    Viewed:740
    Downloaded:21
    Open Access
    Original Article
    Effect of vitamin D supplementation on inflammatory markers and total antioxidant capacity in breast cancer women using a machine learning technique
    Aim: This study aimed to establish a learning system using an artificial neural network (ANN) to predict the effects of vitamin D supplementation on the serum levels of vitamin D, inflammatory fa...
    Marzieh Tahmasebi ... Amir Jamshidnezhad
    Published: October 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00180
    Viewed:527
    Downloaded:13
    Open Access
    Review
    A review on in silico virtual screening methods in COVID-19 using anticancer drugs and other natural/chemical inhibitors
    The present coronavirus disease 2019 (COVID-19) pandemic scenario has posed a difficulty for cancer treatment. Even under ideal conditions, malignancies like small cell lung cancer (SCLC) are challe...
    Babak Sokouti
    Published: October 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00177
    Viewed:618
    Downloaded:22
    Open Access
    Review
    Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer
    Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) is now a drugable oncogenic driver and the KRAS G12C variant responds clinically to sotorasib and adagrasib that covalently block the cystein...
    Gerhard Hamilton ... Barbara Rath
    Published: October 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00178
    Viewed:797
    Downloaded:19
    Open Access
    Systematic Review
    Effect of coronavirus disease 2019 on diagnosis and treatment of hepatocellular carcinoma: a systematic review
    Aim: Changes in strategies in the coronavirus disease 2019 (COVID-19) crisis and the imposing of restrictions have isolated many vulnerable patients including those with hepatocellular carcinoma ...
    Afrooz Mazidimoradi ... Hamid Salehiniya
    Published: October 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00179
    Viewed:661
    Downloaded:12
    Open Access
    Systematic Review
    Current role of artificial intelligence in head and neck cancer surgery: a systematic review of literature
    Aim: Artificial intelligence (AI) is a new field of science in which computers will provide decisions-supporting tools to help doctors make difficult clinical choices. Recent AI applications in o...
    Antonella Loperfido ... Gianluca Bellocchi
    Published: October 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00174
    Viewed:777
    Downloaded:17
    Open Access
    Review
    Biomarkers in renal cell carcinoma and their targeted therapies: a review
    Renal cell carcinoma (RCC) is one of the most life-threatening urinary malignancies displaying poor response to radiotherapy and chemotherapy. Although in the recent past there have been tremendous ...
    Shruti Gupta, Shamsher Singh Kanwar
    Published: October 25, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00175
    Viewed:647
    Downloaded:19
    Open Access
    Review
    Melatonin, BAG-1 and cortisol circadian interactions in tumor pathogenesis and patterned immune responses
    A dysregulated circadian rhythm is significantly associated with cancer risk, as is aging. Both aging and circadian dysregulation show suppressed pineal melatonin, which is indicated in many studies...
    George Anderson
    Published: October 25, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00176
    Viewed:863
    Downloaded:20
    Open Access
    Review
    Molecular interaction of metastasis suppressor genes and tumor microenvironment in breast cancer
    Breast cancer (BC) is a leading cause of cancer-related deaths in women worldwide where the process of metastasis is a major contributor to the mortality associated with this disease. Metastasis sup...
    Sathammai Sathappa Supuramanian ... Sitaram Harihar
    Published: October 11, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00173
    Viewed:876
    Downloaded:28
    Open Access
    Review
    Understanding the feasibility of chemotherapeutic and immunotherapeutic targets against non-small cell lung cancers: an update of resistant responses and recent combinatorial therapies
    Despite consistent progress in prompt diagnosis and curative therapies in the last decade, lung cancer (LC) continues to threaten mankind, accounting for nearly twice the casualties compared to pros...
    Parth Malik ... Tapan Kumar Mukherjee
    Published: October 10, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00171
    Viewed:800
    Downloaded:28
    Open Access
    Original Article
    Exploring the implications of modified advanced lung cancer inflammation index on outcomes in patients with advanced non-small cell lung cancer
    Aim: Sarcopenia and skeletal muscle density (SMD) have been shown to be both predictive and prognostic marker in oncology. Advanced lung cancer inflammation index (ALI) has been shown to predict ...
    Abhishek Mahajan ... Kumar Prabhash
    Published: October 11, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00172
    Viewed:705
    Downloaded:20
    Open Access
    Review
    AGEs and RAGE: metabolic and molecular signatures of the glycation-inflammation axis in malignant or metastatic cancers
    From attributing mutations to cancers with the advent of cutting-edge genetic technology in recent decades, to re-searching the age-old theory of intrinsic metabolic shift of cancers (Warburg’s gl...
    Gowri Palanissami, Solomon F.D. Paul
    Published: September 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00170
    Viewed:1637
    Downloaded:26
    Open Access
    Review
    Malignant tumors of the external auditory canal: diagnosis, treatment, genetic landscape, biomarkers, and clinical outcome
    Malignant tumors of the external auditory canal (EAC) are rare neoplasms that appear in the head and neck area. A common feature of these malignancies is their rarity, as well as their delayed diagn...
    Pinelopi Samara ... Ioannis Athanasopoulos
    Published: September 21, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00169
    Viewed:953
    Downloaded:25
    Open Access
    Original Article
    A single experience in the conduction of clinical trial during COronaVIrusDisease-2019 pandemic
    Aim: From the start of the pandemic, several aspects of healthcare policies changed, not least the clinical trials management from recruiting capabilities to the protocol compliance in terms of s...
    Zelmira Ballatore ... Rossana Berardi
    Published: September 07, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00168
    Viewed:680
    Downloaded:19
    Open Access
    Original Article
    Aflatoxin B1-DNA adducts modify the effects of post-operative adjuvant transarterial chemoembolization improving hepatocellular carcinoma prognosis
    Aim: DNA damage involves in the carcinogenesis of some cancer and may act as a target for therapeutic intervention of cancers. However, it is unclear whether aflatoxin B1 (AFB1)-DNA adducts (ADAs)...
    Liyan Huang ... Xidai Long
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00167
    Viewed:593
    Downloaded:18
    Open Access
    Original Article
    In silico targeting of colony-stimulating factor-1 receptor: delineating immunotherapy in cancer
    Aim: Delineate structure-based inhibition of colony-stimulating factor-1 receptor (CSF1R) by small molecule CSF1R inhibitors in clinical development for target identification and potential lead o...
    Zahra Azhar ... Zohaib Raza
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00164
    Viewed:553
    Downloaded:20
    Open Access
    Original Article
    Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity
    Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistan...
    Melissa Bersanelli ... Luca Ampollini
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00165
    Viewed:487
    Downloaded:12
    Open Access
    Review
    Medicinal chemistry advances in targeting class I histone deacetylases
    Histone deacetylases (HDACs) are a class of zinc (Zn)-dependent metalloenzymes that are responsible for epigenetic modifications. HDACs are largely associated with histone proteins that regulate gen...
    Diaaeldin I. Abdallah ... Patrick T. Gunning
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00166
    Viewed:1205
    Downloaded:50
    Open Access
    Review
    Nanomedicine strategies to counteract cancer stemness and chemoresistance
    Cancer stem-like cells (CSCs) identified by self-renewal ability and tumor-initiating potential are responsible for tumor recurrence and metastasis in many cancers. Conventional chemotherapy fails t...
    Huayu Liu ... Ran Mo
    Published: August 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00157
    Viewed:538
    Downloaded:21
    Open Access
    Original Article
    Deep learning based automated epidermal growth factor receptor and anaplastic lymphoma kinase status prediction of brain metastasis in non-small cell lung cancer
    Aim: The aim of this study was to investigate the feasibility of developing a deep learning (DL) algorithm for classifying brain metastases from non-small cell lung cancer (NSCLC) into epidermal ...
    Abhishek Mahajan ... Kumar Prabhash
    Published: August 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00158
    Viewed:717
    Downloaded:17
    Open Access
    Original Article
    Deep learning based clinico-radiological model for paediatric brain tumor detection and subtype prediction
    Aim: Early diagnosis of paediatric brain tumors significantly improves the outcome. The aim is to study magnetic resonance imaging (MRI) features of paediatric brain tumors and to develop an auto...
    Abhishek Mahajan ... Aliasgar Moiyadi
    Published: August 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00159
    Viewed:642
    Downloaded:17
    Open Access
    Perspective
    Artificial intelligence ethics in precision oncology: balancing advancements in technology with patient privacy and autonomy
    Precision oncology is a rapidly evolving field that uses advanced technologies to deliver personalized cancer care based on a patient’s unique genetic and clinical profile. The use of artificial i...
    Bahareh Farasati Far
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00160
    Viewed:635
    Downloaded:23
    Open Access
    Review
    Anticancer action of naturally occurring emodin for the controlling of cervical cancer
    One of the major causes of death on the globe is cancer. The fourth most frequent malignancy in women worldwide is cervical cancer. Several cancer patients are remaining incurable due to the emergen...
    Priyanka S. Lande ... Leena P. Joge
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00161
    Viewed:653
    Downloaded:19
    Open Access
    Original Article
    Clinical and mutational profile of AT-rich interaction domain 1A-mutated cancers
    Aim: AT-rich interaction domain 1A (ARID1A) encodes a key component of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex that participates in gene expression. ARID1A alter...
    Rosa Falcone ... Gennaro Daniele
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00163
    Viewed:484
    Downloaded:15
    Open Access
    Review
    Protein ISGylation: a posttranslational modification with implications for malignant neoplasms
    Interferon (IFN)-stimulated gene 15 (ISG15) is a member of the ubiquitin-like (UBL) protein family that can modify specific proteins via a catalytic process called ISGylation. This posttranslational...
    Angeles C. Tecalco-Cruz, Jesús Zepeda-Cervantes
    Published: August 31, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00162
    Viewed:614
    Downloaded:19
    Open Access
    Review
    Nuclear epidermal growth factor receptor as a therapeutic target
    Epidermal growth factor receptor (EGFR) is one of the most well-studied oncogenes with roles in proliferation, growth, metastasis, and therapeutic resistance. This intense study has led to the devel...
    Benjamin Atwell ... Joyce Schroeder
    Published: August 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00156
    Viewed:663
    Downloaded:21
    Open Access
    Review
    Aspirin and the metabolic hallmark of cancer: novel therapeutic opportunities for colorectal cancer
    Aspirin is a well-known nonsteroidal anti-inflammatory drug (NSAID) that has a recognized role in cancer prevention as well as evidence to support its use as an adjuvant for cancer treatment. Import...
    Ashley J. Hoskin ... Emma E. Vincent
    Published: August 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00155
    Viewed:822
    Downloaded:22
    Open Access
    Perspective
    Potential tactics with certain gut microbiota for the treatment of unresectable hepatocellular carcinoma
    Hepatocellular carcinoma (HCC) constitutes an extremely malignant form of primary liver cancer. Intricate connections linking to the immune system might be associated with the pathogenesis of HCC. M...
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: August 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00152
    Viewed:1614
    Downloaded:667
    Open Access
    Review
    Emerging role of quantitative imaging (radiomics) and artificial intelligence in precision oncology
    Cancer is a fatal disease and the second most cause of death worldwide. Treatment of cancer is a complex process and requires a multi-modality-based approach. Cancer detection and treatment starts w...
    Ashish Kumar Jha ... Andre Dekker
    Published: August 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00153
    Viewed:902
    Downloaded:20
    Open Access
    Review
    B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease
    Targeting the B-cell lymphoma 2 (Bcl-2) family proteins has been the backbone for hematological malignancies with overall survival improvements. The Bcl-2 family is a major player in apoptosis regul...
    Rui Caetano Oliveira ... José Casanova
    Published: August 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00154
    Viewed:487
    Downloaded:24
    Open Access
    Review
    Current role of machine learning and radiogenomics in precision neuro-oncology
    In the past few years, artificial intelligence (AI) has been increasingly used to create tools that can enhance workflow in medicine. In particular, neuro-oncology has benefited from the use of AI a...
    Teresa Perillo ... Andrea Manto
    Published: July 19, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00151
    Viewed:718
    Downloaded:36
    Open Access
    Review
    Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential
    Cancer remains the second leading cause of death worldwide despite modern breakthroughs in medicine, and novel treatments are urgently needed. The revolutionary success of immune checkpoint inhibito...
    Eric Jou
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00146
    Viewed:778
    Downloaded:22
    Open Access
    Case Report
    Spontaneous regression of a metastatic carcinoma transmitted by a kidney graft
    Transmission of a malignancy from a donor’s organ to the recipient of the graft is a rare event, though it is a severe complication that can result in a poor outcome. Usually, immunosuppressive th...
    Mikhail V. Kiselevskiy ... Irina Zh. Shubina
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00148
    Viewed:499
    Downloaded:15
    Open Access
    Review
    Increasing differential diagnosis between lipoma and liposarcoma through radiomics: a narrative review
    Soft tissue sarcomas (STSs) are rare, heterogeneous, and very often asymptomatic diseases. Their diagnosis is fundamental, as is the identification of the degree of malignancy, which may be high, me...
    Raffaele Natella ... Antonella Santone
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00147
    Viewed:783
    Downloaded:24
    Open Access
    Review
    Glucose metabolism reprogramming promotes immune escape of hepatocellular carcinoma cells
    Hepatocellular carcinoma (HCC) is a complex process that plays an important role in its progression. Abnormal glucose metabolism in HCC cells can meet the nutrients required for the occurrence and d...
    Qiuyue Zhang ... Mengsen Li
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00149
    Viewed:859
    Downloaded:25
    Open Access
    Review
    An introductory review of post-resection chemotherapeutics for primary brain tumors
    The treatment of central nervous system (CNS) tumors is complicated by high rates of recurrence and treatment resistance that contribute to high morbidity and mortality (Nat Rev Neurol. 2022;18:221...
    Meaghan McGovern ... Brandon Lucke-Wold
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00150
    Viewed:797
    Downloaded:33
    Open Access
    Review
    Artificial intelligence and radiomics in magnetic resonance imaging of rectal cancer: a review
    Rectal cancer (RC) is one of the most common tumours worldwide in both males and females, with significant morbidity and mortality rates, and it accounts for approximately one-third of colorectal ca...
    Giuseppe Di Costanzo ... Enrico Cavaglià
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00142
    Viewed:810
    Downloaded:23
    Open Access
    Original Article
    Liquid biopsy: an examination of platelet RNA obtained from head and neck squamous cell carcinoma patients for predictive molecular tumor markers
    Aim: Recently, a tumor cell-platelet interaction was identified in different tumor entities, resulting in a transfer of tumor-derived RNA into platelets, named further “tumor-educated platelets...
    Lisa T. Huber ... Cornelia Brunner
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00143
    Viewed:725
    Downloaded:17
    Open Access
    Original Article
    Continuous enzyme activity assay for high-throughput classification of histone deacetylase 8 inhibitors
    Aim: Human histone deacetylase 8 (KDAC8) is a well-recognized pharmaceutical target in Cornelia de Lange syndrome and different types of cancer, particularly childhood neuroblastoma. Several clas...
    Markus Schweipert ... Franz-Josef Meyer-Almes
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00144
    Viewed:516
    Downloaded:22
    Open Access
    Perspective
    Potential tactics with vitamin D and certain phytochemicals for enhancing the effectiveness of immune-checkpoint blockade therapies
    Immunotherapy strategies targeting immune checkpoint molecules such as programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) are revolutionizing oncology. However, ...
    Ai Tsuji ... Satoru Matsuda
    Published: June 30, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00145
    Viewed:1758
    Downloaded:793
    Open Access
    Review
    Capitalizing glycomic changes for improved biomarker-based cancer diagnostics
    Cancer serum biomarkers are valuable or even indispensable for cancer diagnostics and/or monitoring and, currently, many cancer serum markers are routinely used in the clinic. Most of those markers ...
    Maria Luísa S. Silva
    Published: June 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00140
    Viewed:607
    Downloaded:23
    Open Access
    Original Article
    Real world outcomes in patients with neuroendocrine tumor receiving peptide receptor radionucleotide therapy
    Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neur...
    Stijn Hentzen ... Anup Kasi
    Published: June 29, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00141
    Viewed:613
    Downloaded:13
    Open Access
    Review
    Transforming growth factor-β signaling: from tumor microenvironment to anticancer therapy
    Transforming growth factor-β (TGF-β) signaling is an important pathway for promoting the pathogenesis of inflammatory diseases, including cancer. The roles of TGF-β signaling are heterogeneous and versatile in cancer development and progression, both anticancer and protumoral actions are reported. Interestingly, increasing evidence suggests that TGF-β enhances disease progression and drug resistance via immune-modulatory actions in the tumor microenvironment (TME) of solid tumors. A better understanding of its regulatory mechanisms in the TME at the molecular level can facilitate the development of precision medicine to block the protumoral actions of TGF-β in the TME. Here, the latest information about the regulatory mechanisms and translational research of TGF-β signaling in the TME for therapeutic development had been summarized....
    Max Kam-Kwan Chan ... Patrick Ming-Kuen Tang
    Published: April 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00137
    Viewed:1210
    Downloaded:47
    Open Access
    Review
    Role of artificial intelligence in oncologic emergencies: a narrative review
    Oncologic emergencies are a wide spectrum of oncologic conditions caused directly by malignancies or their treatment. Oncologic emergencies may be classified according to the underlying physiopathol...
    Salvatore Claudio Fanni ... Emanuele Neri
    Published: April 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00138
    Viewed:1125
    Downloaded:37
    Open Access
    Original Article
    Small cell lung cancer: circulating tumor cell lines and expression of mediators of angiogenesis and coagulation
    Aim: Coagulation is frequently activated in cancer patients and has been correlated with an unfavorable prognosis. To evaluate whether a putative release of tissue factor (TF) by circulating tumor ...
    Barbara Rath ... Gerhard Hamilton
    Published: April 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00139
    Viewed:831
    Downloaded:25
    Open Access
    Original Article
    Development and validation of an infrared-artificial intelligence software for breast cancer detection
    Aim: In countries where access to mammography equipment and skilled personnel is limited, most breast cancer (BC) cases are detected in locally advanced stages. Infrared breast thermography is reco...
    Enrique Martín-Del-Campo-Mena ... Yessica González-Mejía
    Published: April 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00135
    Viewed:1495
    Downloaded:36
    Open Access
    Systematic Review
    Anticancer of genus Syzygium: a systematic review
    Aim: One in eight fatalities globally are considered cancer-related. The need for cancer therapy is growing. Natural products continue to play a role in drug development, as up to 50% of authorized...
    Mahmoud Dogara Abdulrahman, Harmand A. Hama
    Published: April 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00134
    Viewed:1084
    Downloaded:32
    Open Access
    Case Report
    Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
    A clinical case of a 61-year-old female diagnosed with stage IV right colon adenocarcinoma (unresectable liver and multiple lymph node metastases at the time of diagnosis), Kirsten rat sarcoma viral...
    Celia Lara-Morga ... Luis Cabezón-Gutiérrez
    Published: April 27, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00136
    Viewed:712
    Downloaded:19
    Open Access
    Case Report
    Cystic presentation of primary hepatic neuroendocrine tumour: a case report with a brief review of literature
    Neuroendocrine tumours (NETs) are a rare type of tumours that arise from the neuroendocrine cells which are distributed throughout the body. Of all the gastrointestinal tumours only 1–2% account for NETs. They have an extremely low incidence of 0.17% arising in the intrahepatic bile duct epithelium. Majority of hepatic NETs occur as a result of metastases from the primary NETs. Most cases of primary hepatic NET (PHNET) present as a solid nodular mass. However, predominantly cystic PHNET is extremely rare which mimics other cystic space-occupying lesions clinically and radiologically as seen in this case....
    Mangesh Londhe ... Charusheela Gore
    Published: April 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00133
    Viewed:605
    Downloaded:13
    Open Access
    Review
    Gut microbiota, an emergent target to shape the efficiency of cancer therapy
    It is now well-acknowledged that microbiota has a profound influence on both human health and illness. The gut microbiota has recently come to light as a crucial element that influences cancer throu...
    Soumaya Kouidhi ... Amel Ben Ammar El Gaaied
    Published: April 26, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00132
    Viewed:1253
    Downloaded:38
    Open Access
    Original Article
    A potent bioactive fraction against colon cancer from Plectranthus vettiveroides
    Aim: This study was designed to investigate the anticancer efficacy of the organic leaf extracts of the plant, Plectranthus vettiveroides (P. vettiveroides), and to analyze the molecular mechanism ...
    Faisal M. Athikkavil ... Smitha V. Bava
    Published: April 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00131
    Viewed:1038
    Downloaded:23
    Open Access
    Letter to the Editor
    Clinicopathological relevance of stem cell marker growth and differentiation factor 3 in esophageal squamous cell carcinoma
    Esophageal squamous cell carcinoma (ESCC) is the second leading cause of cancer-related deaths in Iran, often diagnosed in advanced stages with a poor prognosis. Growth and differentiation factor 3 ...
    Sara Tahbazzadeh Moghaddam, Mohammad Mahdi Forghanifard
    Published: April 24, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00130
    Viewed:606
    Downloaded:16
    Open Access
    Review
    Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications
    The Raf kinase inhibitor protein (RKIP) has been reported to be underexpressed in many cancers and plays a role in the regulation of tumor cells' survival, proliferation, invasion, and me...
    Matthew Moghaddam ... Benjamin Bonavida
    Published: April 20, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00128
    Viewed:994
    Downloaded:29
    Open Access
    Review
    Ginnalin A and hamamelitannin: the unique gallotannins with promising anti-carcinogenic potential
    Tannins are secondary metabolites that belong to the family of polyphenolic compounds and have gained a huge interest among researchers due to their versatile therapeutic potential. After lignin, th...
    Rippin ... Anil K. Sharma
    Published: April 21, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00129
    Viewed:825
    Downloaded:21
    Open Access
    Review
    Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer
    Liquid biopsy is a diagnostic repeatable test, which in last years has emerged as a powerful tool for profiling cancer genomes in real-time with minimal invasiveness and tailoring oncological decisi...
    Vincenza Caputo ... Stefania Napolitano
    Published: February 28, 2023 Explor Target Antitumor Ther DOI: 10.37349/etat.2023.00125
    Viewed:1826
    Downloaded:61
    Open Access
    Review
    Research progress in molecular pathology markers in medulloblastoma
    Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on ne...
    Zixuan Zhou ... Shangfeng Gao
    Published: February 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00126
    Viewed:991
    Downloaded:26
    Open Access
    Review
    Artificial intelligence applications in pediatric oncology diagnosis
    Artificial intelligence (AI) algorithms have been applied in abundant medical tasks with high accuracy and efficiency. Physicians can improve their diagnostic efficiency with the assistance of AI techniques for improving the subsequent personalized treatment and surveillance. AI algorithms fundamentally capture data, identify underlying patterns, achieve preset endpoints, and provide decisions and predictions about real-world events with working principles of machine learning and deep learning. AI algorithms with sufficient graphic processing unit power have been demonstrated to provide timely diagnostic references based on preliminary training of large amounts of clinical and imaging data. The sample size issue is an inevitable challenge for pediatric oncology considering its low morbidity and individual heterogeneity. However, this problem may be solved in the near future considering the exponential advancements of AI algorithms technically to decrease the dependence of AI operation on the amount of data sets and the efficiency of computing power. For instance, it could be a feasible solution by shifting convolutional neural networks (CNNs) from adults and sharing CNN algorithms across multiple institutions besides original data. The present review provides important insights into emerging AI applications for the diagnosis of pediatric oncology by systematically overviewing of up-to-date literature....
    Yuhan Yang ... Yuan Li
    Published: February 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00127
    Viewed:1068
    Downloaded:29
    Open Access
    Original Article
    Enhancement of reactive oxygen species production in triple negative breast cancer cells treated with electric pulses and resveratrol
    Aim: Triple negative breast cancer (TNBC) is difficult to treat since it lacks all the three most commonly targeted hormone receptors. Patients afflicted with TNBC are treated with platinum core ...
    Pragatheiswar Giri ... Raji Sundararajan
    Published: February 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00122
    Viewed:833
    Downloaded:24
    Open Access
    Systematic Review
    Crude extract of Ficus deltoidea Jack (FD) as a natural biological therapy
    Aim: This study shows how important it is to coordinate research on Ficus deltoidea Jack (FD) so that results from different sources can be compared directly and a scientific conclusion can be made. Methods: The author looked for research papers on Ficus (F.) deltoidea on Google Scholar, Science Direct, Google.com, Wiley, PubMed, Hindawi, Springer, and other related databases. This analysis excludes data that cannot be trusted, thesis papers, and review articles about F. deltoidea. Results: In traditional medicine, the plant’s leaves and syconia are used to cure a wide variety of ailments, including itchiness, diarrhoea, cancer, sexual dysfunction, age-related issues, malaria, cancer, anxiety, pain, constipation, fever, diabetes, tooth pain, and tooth decay. In vitro and in vivo studies showed the effectiveness of the leaves against cancer cell lines. Conclusions: Based on the existing research on the health benefits of FD, it is critical to focus on its more active constituents and their identification, determination, further development, and, most importantly, standardization of the leaves for the management and treatment of cancer and its related cases. More research is needed before it can be considered a promising herbal source of novel medication candidates for treating various disorders....
    Mahmoud Dogara Abdulrahman
    Published: February 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00123
    Viewed:914
    Downloaded:17
    Open Access
    Review
    Macrophages as potential targets in gene therapy for cancer treatment
    Macrophages, as ubiquitous and functionally diverse immune cells, play a central role in innate immunity and initiate adaptive immunity. Especially, tumor-associated macrophages (TAMs) are crucial c...
    Yuanzheng Huang ... Xiaoxuan Liu
    Published: February 28, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00124
    Viewed:1435
    Downloaded:43
    Open Access
    Review
    Liquid biopsy and glioblastoma
    Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on ne...
    Robert H. Eibl, Markus Schneemann
    Published: February 25, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00121
    Viewed:1664
    Downloaded:38
    Open Access
    Perspective
    A primer on cancer-associated fibroblast mechanics and immunosuppressive ability
    Cancer-associated fibroblasts (CAFs) are a major point of interest in modern oncology. Their interest resides in their ability to favor tumor growth without carrying genetic mutations. From a transl...
    Vanessa C. Talayero, Miguel Vicente-Manzanares
    Published: February 20, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00120
    Viewed:823
    Downloaded:24
    Open Access
    Original Article
    Artificial intelligence fusion for predicting survival of rectal cancer patients using immunohistochemical expression of Ras homolog family member B in biopsy
    Aim: The process of biomarker discovery is being accelerated with the application of artificial intelligence (AI), including machine learning. Biomarkers of diseases are useful because they are i...
    Tuan D. Pham ... Xiao-Feng Sun
    Published: February 07, 2023 Explor Target Antitumor Ther. DOI: 10.37349/etat.2023.00119
    Viewed:885
    Downloaded:35
    Open Access
    Review
    New phase therapeutic pursuits for targeted drug delivery in glioblastoma multiforme
    Glioblastoma multiforme (GBM) is known as the most aggressive and prevalent brain tumor with a high mortality rate. It is reported in people who are as young as 10 years old to as old as over 70 years old, exhibiting inter and intra tumor heterogeneity. There are several genomic and proteomic investigations that have been performed to find the unexplored potential targets of the drug against GBM. Therefore, certain effective targets have been taken to further validate the studies embarking on the robustness in the field of medicinal chemistry followed by testing in clinical trials. Also, The Cancer Genome Atlas (TCGA) project has identified certain overexpressed targets involved in the pathogenesis of GBM in three major pathways, i.e., tumor protein 53 (p53), retinoblastoma (RB), and receptor tyrosine kinase (RTK)/rat sarcoma virus (Ras)/phosphoinositide 3-kinase (PI3K) pathways. This review focuses on the compilation of recent developments in the fight against GBM thus, directing future research into the elucidation of pathogenesis and potential cure for GBM. Also, it highlights the potential biomarkers that have undergone extensive research and have promising prognostic and predictive values. Additionally, this manuscript analyses the advent of gene therapy and immunotherapy, unlocking the way to consider treatment approaches other than, or in addition to, conventional chemo-radiation therapies. This review study encompasses all the relevant research studies associated with the pathophysiology, occurrence, diagnostic tools, and therapeutic intervention for GBM. It highlights the evolution of various therapeutic perspectives against GBM from the most conventional form of radiotherapy to the recent advancement of gene/cell/immune therapy. Further, the review focuses on various targeted therapies for GBM including chemotherapy sensitization, radiotherapy, nanoparticles based, immunotherapy, cell therapy, and gene therapy which would offer a comprehensive account for exploring several facets related to GBM prognostics....
    Manisha Singh ... Rachana
    Published: December 30, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00118
    Viewed:1254
    Downloaded:51
    Open Access
    Original Article
    Evaluating immune response in vitro in a relevant microenvironment: a high-throughput microfluidic model for clinical screening
    Aim: Functional screening of new pharmaceutical compounds requires clinically relevant models to monitor essential cellular and immune responses during cancer progression, with or without treatment. Beyond survival, the emergence of resistant tumor cell clones should also be considered, including specific properties related to plasticity, such as invasiveness, stemness, escape from programmed cell death, and immune response. Numerous pathways are involved in these processes. Defining the relevant ones in the context of a specific tumor type will be key to designing an appropriate combination of inhibitors. However, the diversity and potential redundancy of these pathways remain a challenge for therapy. Methods: A new microfluidic device developed by Okomera was dedicated to the screening of drug treatment for breast cancer. This microchip includes 150 droplet-trapping microwells, offering multi-chip settings and multiple treatment choices. Results: After validating the system with established cell lines and a panel of drugs used clinically at Gustave Roussy, preclinical experiments were initiated including patient-derived xenograft (PDX) and primary tumor cells-derived tumoroids with the collaboration of Gustave Roussy clinicians. Tumor-isolated lymphocytes were also added to the tumoroids, using secondary droplets in proof-of-concept experiments. Conclusions: These results show the relevance of the methodology for screening large numbers of drugs, a wide range of doses, and multiple drug combinations. This methodology will be used for two purposes: 1) new drug screening from the compound library, using the high throughput potential of the chip; and 2) pre-clinical assay for a two-weeks response for personalized medicine, allowing evaluation of drug combinations to flag an optimized treatment with potential clinical application....
    Flora Doffe ... Pierre Savagner
    Published: December 29, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00117
    Viewed:1192
    Downloaded:59
    Open Access
    Commentary
    De novo cholesterol biosynthesis: an additional therapeutic target for the treatment of postmenopausal breast cancer with excessive adipose tissue
    The onset and development of breast cancer in postmenopausal women are associated with closely related individual-dependent factors, including weight gain and high levels of circulating androgens. Adipose tissue is the most peripheral site of aromatase enzyme synthesis; therefore, the excessive accumulation of visceral fat results in increased androgens aromatization and estradiol production that provides the microenvironment favorable to tumorigenesis in mammary epithelial cells expressing estrogen receptors (ERs). Moreover, to meet the increased requirement of cholesterol for cell membrane assembly and the production of steroid hormones to sustain their proliferation, ER-positive cells activate de novo cholesterol biosynthesis and subsequent steroidogenesis. Several approaches have been followed to neutralize the de novo cholesterol synthesis, including specific enzyme inhibitors, statins, and, more recently, metformin. Cumulating evidence indicated that inhibiting cholesterol biosynthesis by statins and metformin may be a promising therapeutic strategy to block breast cancer progression. Unlike antiestrogens and aromatase inhibitors (AIs) which compete for binding to ER and inhibit androgens aromatization, respectively, statins block the production of mevalonic acid by inhibiting the activity of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and metformin hampers the activation of the sterol regulatory element-binding protein 2 (SREBP2) transcription factor, thus inhibiting the synthesis of several enzymes involved in cholesterol biosynthesis. Noteworthy, statins and metformin not only improve the prognosis of overweight patients with ER-positive cancer but also improve the prognosis of patients with triple-negative breast cancer, the aggressive tumor subtype that lacks, at present, specific therapy....
    Danila Coradini
    Published: December 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00116
    Viewed:869
    Downloaded:22
    Open Access
    Review
    Antibody-drug conjugates for lymphoma patients: preclinical and clinical evidences
    Antibody-drug conjugates (ADCs) are a recent, revolutionary approach for malignancies treatment, designed to provide superior efficacy and specific targeting of tumor cells, compared to systemic cyt...
    Marilia Barreca ... Francesco Bertoni
    Published: December 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00112
    Viewed:1734
    Downloaded:61
    Open Access
    Review
    Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis—a narrative review
    The advent of artificial intelligence (AI) represents a real game changer in today’s landscape of breast cancer imaging. Several innovative AI-based tools have been developed and validated in recent years that promise to accelerate the goal of real patient-tailored management. Numerous studies confirm that proper integration of AI into existing clinical workflows could bring significant benefits to women, radiologists, and healthcare systems. The AI-based approach has proved particularly useful for developing new risk prediction models that integrate multi-data streams for planning individualized screening protocols. ...
    Maurizio Cè ... Michaela Cellina
    Published: December 27, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00113
    Viewed:1701
    Downloaded:58
    Open Access
    Perspective
    Encouraging probiotics for the prevention and treatment of immune-related adverse events in novel immunotherapies against malignant glioma
    Among the malignant tumors in the central nervous system (CNS), glioma is the most challenging tumor to the public society, which accounts for the majority of intracranial malignant tumors with impa...
    Sayuri Yoshikawa ... Satoru Matsuda
    Published: December 27, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00114
    Viewed:2916
    Downloaded:1307
    Open Access
    Original Article
    Dendritic cell-targeting chemokines inhibit colorectal cancer progression
    Aim: Recent progress in cancer immunotherapy has shown its promise and prompted researchers to develop novel therapeutic strategies. Dendritic cells (DCs) are professional antigen-presenting cell...
    Pengkun Yuan ... Bin Ma
    Published: December 27, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00115
    Viewed:1135
    Downloaded:27
    Open Access
    Review
    Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
    Major advances in cancer treatment have emerged with the introduction of immunotherapies using blocking antibodies that target T-cell inhibitory receptors, such as programmed death-1 (PD-1) and cyto...
    Mohamad Omar Ashi ... Stéphanie Corgnac
    Published: December 22, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00111
    Viewed:1301
    Downloaded:55
    Open Access
    Systematic Review
    Diffusion-weighted imaging and apparent diffusion coefficient mapping of head and neck lymph node metastasis: a systematic review
    Aim: Head and neck squamous cell cancer (HNSCC) is the ninth most common tumor worldwide. Neck lymph node (LN) status is the major indicator of prognosis in all head and neck cancers, and the early detection of LN involvement is crucial in terms of therapy and prognosis. Diffusion-weighted imaging (DWI) is a non-invasive imaging technique used in magnetic resonance imaging (MRI) to characterize tissues based on the displacement motion of water molecules. This review aims to provide an overview of the current literature concerning quantitative diffusion imaging for LN staging in patients with HNSCC. Methods: This systematic review performed a literature search on the PubMed database (https://pubmed.ncbi.nlm.nih.gov/) for all relevant, peer-reviewed literature on the subject following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) criteria, using the keywords: DWI, MRI, head and neck, staging, lymph node. Results: After excluding reviews, meta-analyses, case reports, and bibliometric studies, 18 relevant papers out of the 567 retrieved were selected for analysis. Conclusions: DWI improves the diagnosis, treatment planning, treatment response evaluation, and overall management of patients affected by HNSCC. More robust data to clarify the role of apparent diffusion coefficient (ADC) and DWI parameters are needed to develop models for prognosis and prediction in HNSCC cancer using MRI. ...
    Maria Paola Belfiore ... Salvatore Cappabianca
    Published: December 13, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00110
    Viewed:1597
    Downloaded:34
    Open Access
    Review
    Onosma L. as a source of anticancer agents: phytochemistry to mechanistic insight
    Onosma (O.) is a genus of perennial flowering plants in the family Boraginaceae with approximately 250 species widely dispersed in temperate, tropical, and subtropical areas. It is traditionally use...
    Ajay Kumar ... Satwinderjeet Kaur
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00109
    Viewed:1142
    Downloaded:50
    Open Access
    Review
    Clinical utility of liquid biopsy-based companion diagnostics in the non-small-cell lung cancer treatment
    Recently, technological advances in the detection and biological characterization of circulating tumor DNA (ctDNA) have enabled the implementation of liquid biopsy testing into clinical practice. Me...
    Yoshiharu Sato
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00104
    Viewed:1447
    Downloaded:24
    Open Access
    Review
    Potential role of resveratrol and its nano-formulation as anti-cancer agent
    The uncontrolled and metastatic nature of cancer makes it worse and more unpredictable. Hence, many therapy and medication are used to control and treat cancer. However, apart from this, many medica...
    Akshay Kumar ... Dilpreet Singh
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00105
    Viewed:1404
    Downloaded:29
    Open Access
    Review
    Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapies
    Steroid use is a widely accepted practice for both the treatment and prevention of tumor-induced edema, but there are many unknowns regarding their current clinical utility with modern anti-tumor th...
    Matthew Goldman ... Stephan Quintin
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00106
    Viewed:989
    Downloaded:26
    Open Access
    Review
    Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers
    In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficit...
    Shiu Ying Tsao
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00107
    Viewed:1298
    Downloaded:22
    Open Access
    Review
    The tumor innate immune microenvironment in prostate cancer: an overview of soluble factors and cellular effectors
    Prostate cancer (PCa) accounts as the most common non-cutaneous disease affecting males, and as the first cancer, for incidence, in male. With the introduction of the concept of immunoscore, PCa has...
    Maria Teresa Palano ... Lorenzo Mortara
    Published: October 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00108
    Viewed:1459
    Downloaded:58
    Open Access
    Original Article
    Targeted RNA-sequencing analysis for fusion transcripts detection in tumor diagnostics: assessment of bioinformatic tools reliability in FFPE samples
    Aim: Diagnostic laboratories are progressively introducing next-generation sequencing (NGS) technologies in the routine workflow to meet the increasing clinical need for comprehensive molecular c...
    Iolanda Capone ... Giancarlo Pruneri
    Published: October 27, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00102
    Viewed:878
    Downloaded:21
    Open Access
    Review
    Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions
    Cancer-associated fibroblasts (CAFs) are highly heterogeneous players that shape the tumor microenvironment and influence tumor progression, metastasis formation, and response to conventional therap...
    Jerome Thiery
    Published: October 27, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00103
    Viewed:1456
    Downloaded:26
    Open Access
    Commentary
    A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
    Solute carrier family 7 member 11 (SLC7A11; also known as xCT), a key component of the cystine/glutamate antiporter, is essential for the maintenance of cellular redox status and the regulation of t...
    Daniela Criscuolo ... Angela Celetti
    Published: October 25, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00101
    Viewed:1224
    Downloaded:35
    Open Access
    Original Article
    N6-methyladenosine-related microRNAs risk model trumps the isocitrate dehydrogenase mutation status as a predictive biomarker for the prognosis and immunotherapy in lower grade gliomas
    Aim: Lower grade gliomas [LGGs; World Health Organization (WHO) grades 2 and 3], owing to the heterogeneity of their clinical behavior, present a therapeutic challenge to ...
    Feng Yuan ... Chiyuan Ma
    Published: September 30, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00100
    Viewed:1366
    Downloaded:40
    Open Access
    Review
    miRNA therapeutics in precision oncology: a natural premium to nurture
    The dynamic spectrum of microRNA (miRNA) has grown significantly over the years with its identification and exploration in cancer therapeutics and is currently identified as an important resource fo...
    Chakresh Kumar Jain ... R Suresh Kumar
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00098
    Viewed:1186
    Downloaded:46
    Open Access
    Review
    Clinical applications of liquid biopsy in HPV-negative and HPV-positive head and neck squamous cell carcinoma: advances and challenges
    Head and neck squamous cell carcinomas (HNSCCs) represent the most common epithelial tumors that arise from mucosa of the oral cavity, pharynx, and larynx. The development of HNSCCs is usually assoc...
    Mariana Chantre-Justino ... Lucas Delmonico
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00099
    Viewed:1794
    Downloaded:64
    Open Access
    Review
    Applications and challenges of biomaterial mediated mRNA delivery
    With the rapid development of gene therapy technology and the outbreak of coronavirus disease 2019 (COVID-19), messenger RNA (mRNA) therapeutics have attracted more and more attention, and the COVID...
    Huapan Fang, Qian Chen
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00093
    Viewed:1728
    Downloaded:42
    Open Access
    Review
    Roles of calcium signaling in cancer metastasis to bone
    Bone metastasis is a frequent complication for cancers and an important reason for the mortality in cancer patients. After surviving in bone, cancer cells can cause severe pain, life-threatening hyp...
    Tianying Xie ... Jianru Xiao
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00094
    Viewed:1512
    Downloaded:44
    Open Access
    Review
    A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors
    Multiple myeloma (MM) is a blood cancer that derives from plasma cells (PCs), which will accumulate in the bone marrow (BM). Over time, several drugs have been developed to treat this disease that i...
    Vincenzo Raimondi ... Nicola Giuliani
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00095
    Viewed:1522
    Downloaded:36
    Open Access
    Review
    Endocrine therapy resistance: what we know and future directions
    Endocrine resistance is a major hurdle in the treatment of estrogen receptor (ER)-positive breast cancer. When abnormally regulated, molecular signals responsible for cellular proliferation, as well...
    David Musheyev, Anya Alayev
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00096
    Viewed:1457
    Downloaded:21
    Open Access
    Review
    Myeloid-derived suppressor cells in colorectal cancer: prognostic biomarkers and therapeutic targets
    Myeloid-derived suppressor cells (MDSCs) are a group of immature myeloid cells, which are expanded in most cancer patients. MDSCs suppress host immune responses, leading to cancer growth and progres...
    Mohammad A. Al-Mterin, Eyad Elkord
    Published: August 31, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00097
    Viewed:1599
    Downloaded:51
    Open Access
    Perspective
    Anticancer action of plant products: changing stereotyped attitudes
    Compared to humans, plants can synthesize an extremely diverse array of chemical compounds, including phenolic acids, flavonoids, stilbenes, lignans, terpenoids, alkaloids, and many other types of s...
    Katrin Sak
    Published: August 15, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00092
    Viewed:1079
    Downloaded:45
    Open Access
    Original Article
    Consequences of the impact of COVID-19 pandemic on breast cancer at a single Italian institution
    Aim: To evaluate the local impact of the coronavirus disease 2019 (COVID-19) pandemic on breast cancer (BC) care, with particular attention to the economical and psychological consequences of the...
    Daniele Ugo Tari ... Fabio Pinto
    Published: July 29, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00091
    Viewed:1068
    Downloaded:52
    Open Access
    Original Article
    Combination of thermal ablation by focused ultrasound, pFAR4-IL-12 transfection and lipidic adjuvant provide a distal immune response
    Aim: Gene-based immunotherapy against cancer is limited by low gene transfer efficiency. In the literature, interleukin-12 (IL-12) encoding plasmid associated with sonoporation has been shown to en...
    Hai Doan Do ... Nathalie Mignet
    Published: June 29, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00090
    Viewed:1866
    Downloaded:93
    Open Access
    Original Article
    Allosteric cross-talk between the hydrophobic cleft and the BH4 domain of Bcl-2 in control of inositol 1,4,5-trisphosphate receptor activity
    Aim: Inositol 1,4,5-trisphosphate receptor (IP3R) is a ubiquitous calcium (Ca2+) channel involved in the regulation of cellular fate and motility. Its modulation by anti-apoptotic prote...
    George Shapovalov ... Natalia Prevarskaya
    Published: June 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00088
    Viewed:1467
    Downloaded:52
    Open Access
    Case Report
    Advanced metastatic pancreatic neuroendocrine tumor treated successfully with peptide receptor radionuclide therapy: a case report
    Neuroendocrine tumor (NET) is a rare tumor that has been observed in different sites such as lungs and throughout the gastrointestinal tract. Clinical features are usually non-specific and vary cons...
    Amit Kumar ... Rohit Kumar
    Published: June 29, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00089
    Viewed:1068
    Downloaded:69
    Open Access
    Review
    Liquid biopsy in biliary tract cancer from blood and bile samples: current knowledge and future perspectives
    Biliary tract cancer (BTC) is an aggressive tumor characterized by a poor prognosis. In the latest years, targetable genetic alterations have been discovered in BTC patients, leading to the approval...
    Gianluca Arrichiello ... Emilio Francesco Giunta
    Published: June 22, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00087
    Viewed:1502
    Downloaded:47
    Open Access
    Review
    Exploring new pathways in endocrine-resistant breast cancer
    The most common breast cancer (BC) subtypes are hormone-dependent, being either estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), or both, and altogether comprise the luminal subtype. The mainstay of treatment for luminal BC is endocrine therapy (ET), which includes several agents that act either directly targeting ER action or suppressing estrogen production. Over the years, ET has proven efficacy in reducing mortality and improving clinical outcomes in metastatic and nonmetastatic BC. However, the development of ET resistance promotes cancer survival and progression and hinders the use of endocrine agents. Several mechanisms implicated in endocrine resistance have now been extensively studied. Based on the current clinical and pre-clinical data, the present article briefly reviews the well-established pathways of ET resistance and continues by focusing on the three most recently uncovered pathways, which may mediate resistance to ET, namely receptor activator of nuclear factor kappa Β ligand (RANKL)/receptor activator of nuclear factor kappa Β (RANK), nuclear factor kappa Β (NFκB), and Notch. It additionally overviews the evidence underlying the approval of combined therapies to overcome ET resistance in BC, while highlighting the relevance of future studies focusing on putative mediators of ET resistance to uncover new therapeutic options for the disease....
    Inês Soares de Pinho ... Luís Costa
    Published: June 20, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00086
    Viewed:1593
    Downloaded:42
    Open Access
    Systematic Review
    Management of lung cancer patients during COVID-19 pandemic: dos, don’ts and don’t knows
    Aim: During the coronavirus disease 2019 (COVID-19) pandemic two needs have overlapped: on one hand continuing to provide the best care for patients with lung cancer and preventing the spread of the...
    Mariangela Torniai ... Rossana Berardi
    Published: June 10, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00085
    Viewed:1093
    Downloaded:35
    Open Access
    Review
    In vitro breast cancer models for studying mechanisms of resistance to endocrine therapy
    The development of endocrine resistance is a common reason for the failure of endocrine therapies in hormone receptor-positive breast cancer. This review provides an overview of the different types ...
    Gary J. Cheng ... Dean C. Singleton
    Published: June 01, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00084
    Viewed:1818
    Downloaded:67
    Open Access
    Review
    Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it
    The antiapoptotic B cell lymphoma-2 (Bcl-2) family members are apical regulators of the intrinsic pathway of apoptosis that orchestrate mitochondrial outer membrane permeabilization (MOMP) through i...
    Prasad Sulkshane, Tanuja Teni
    Published: May 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00083
    Viewed:1726
    Downloaded:42
    Open Access
    Review
    Antibody-drug conjugates: beyond current approvals and potential future strategies
    The recent approvals for antibody-drug conjugates (ADCs) in multiple malignancies in recent years have fuelled the ongoing development of this class of drugs. These novel agents combine the benefits...
    Siddharth Menon ... Hui K. Gan
    Published: April 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00082
    Viewed:4755
    Downloaded:205
    Open Access
    Perspective
    Endocrine resistant breast cancer: brain metastasis
    Endocrine resistant breast cancer metastasis continues to serve as a significant clinical challenge with high morbidity and mortality for patients. As the number of breast cancer cases continues to ...
    Matthew Willman ... Brandon Lucke-Wold
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00081
    Viewed:1527
    Downloaded:39
    Open Access
    Review
    Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
    Improving the survival of patients with cholangiocarcinoma (CCA) has long proved challenging, although the treatment of this disease nowadays is on advancement. The historical invariability of survi...
    Marianeve Carotenuto ... Nicola Normanno
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00079
    Viewed:2604
    Downloaded:59
    Open Access
    Original Article
    The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer
    Aim: Zinc is a key secondary messenger that can regulate multiple signalling pathways within cancer cells, thus its levels need to be strictly controlled. The Zrt, Irt-like protein (ZIP, SLC39A) ...
    Samuel Jones ... Kathryn M. Taylor
    Published: April 26, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00080
    Viewed:2015
    Downloaded:78
    Open Access
    Review
    Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic
    The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a...
    Aglaia Skolariki ... Simon Lord
    Published: April 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00078
    Viewed:2290
    Downloaded:73
    Open Access
    Review
    Advancing antibody-drug conjugates in gynecological malignancies: myth or reality?
    Antibody-drug conjugates (ADCs) represent a new class of therapeutic agents designed to target specific antigens on tumor cells, combining the specificity of monoclonal antibodies to the cytotoxicit...
    Marta Nerone ... Ilaria Colombo
    Published: April 19, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00077
    Viewed:3446
    Downloaded:101
    Open Access
    Review
    Yeast as a tool to decipher the molecular mechanisms underlying the functions of Bcl-2 family
    The budding yeast Saccharomyces cerevisiae, a favorite model in biology, does not contain any protein of the Bcl-2 family. From initial experiments with two-hybrid systems to the heterologous expression of human Bcl-2 family members, and the characterization of several forms of yeast programmed cell death, ...
    Stéphen Manon
    Published: April 02, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00076
    Viewed:1663
    Downloaded:43
    Open Access
    Review
    Polyester materials for mRNA delivery
    Messenger RNA (mRNA) has recently made important progress in clinical implementation, offering a promising therapeutic option for infectious disease and cancer. However, the nature of mRNA molecules...
    Wang Chen ... Dandan Zhu
    Published: March 11, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00075
    Viewed:1986
    Downloaded:116
    Open Access
    Review
    Targeting the two-pore channel 2 in cancer progression and metastasis
    The importance of Ca2+ signaling, and particularly Ca2+ channels, in key events of cancer cell function such as proliferation, metastasis, autophagy and angiogenesis, has recently begun to be appreciated. Of particular note are two-pore channels (TPCs), a group of recently identified Ca2+-channels, located within the endolysosomal system. ...
    Kathryn A. Skelding ... Lisa F. Lincz
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00072
    Viewed:2007
    Downloaded:51
    Open Access
    Case Report
    Liver venous deprivation for resection of advanced hilar cholangiocarcinoma—a case report and review of the literature
    Hilar cholangiocarcinoma is a rare primary malignancy associated with a dismal prognosis. Currently, complete extended right or left-sided hepatectomy is the primary curative therapy. Achieving a ne...
    Radoslava Stoyanova ... Alexander Klaus
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00073
    Viewed:1330
    Downloaded:51
    Open Access
    Original Article
    Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model
    Aim: A model of progressively endocrine-resistant breast cancer was investigated to identify changes that can occur in signaling pathways after endocrine manipulation. Methods: The MCF7 breas...
    Kate M. Moore ... Simon P. Langdon
    Published: February 28, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00074
    Viewed:1559
    Downloaded:70
    Open Access
    Review
    New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
    Antibody-drug conjugates (ADCs) have changed the treatment of breast cancer (BC) in more recent years. BC is a heterogenous group of malignancies with a broad range of histopathological characterist...
    Kira-Lee Koster ... Markus Joerger
    Published: February 24, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00069
    Viewed:3184
    Downloaded:92
    Open Access
    Original Article
    B-cell receptor dependent phagocytosis and presentation of particulate antigen by chronic lymphocytic leukemia cells
    Aim: T-helper cells could play an important role in the pathogenesis of chronic lymphocytic leukemia (CLL), a common B-cell neoplasm. Although CLL cells can present soluble antigens targeted from...
    Annabel R. Minton ... Graham Packham
    Published: February 25, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00070
    Viewed:2019
    Downloaded:68
    Open Access
    Review
    Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics
    During the past two decades, tremendous progress has been made in the dendrimer-based delivery of therapeutic molecules including, for instance, small molecules, macromolecules, and genes. This revi...
    Serge Mignani ... Jean-Pierre Majoral
    Published: February 25, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00071
    Viewed:1394
    Downloaded:44
    Open Access
    Original Article
    Bcl-2-like protein-10 increases aggressive features of melanoma cells
    Aim: B-cell lymphoma-2 (Bcl-2)-like protein-10 (Bcl2L10) is the less studied member of Bcl-2 family proteins, with the controversial role in different cancer histotypes. Very recently, Bcl2L10 ex...
    Donatella Del Bufalo ... Simona D’Aguanno
    Published: January 30, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00068
    Viewed:1884
    Downloaded:71
    Open Access
    Review
    Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
    Targeted immunotherapy has arisen over the past decade to the forefront of cancer care. Notably, targeted therapies such as antibody-drug conjugates (ADCs) are becoming more recognized for a novel a...
    Monique Hartley-Brown, Paul Richardson
    Published: January 14, 2022 Explor Target Antitumor Ther. DOI: 10.37349/etat.2022.00067
    Viewed:2724
    Downloaded:118
    Open Access
    Review
    Interface between obesity with dysfunctional metabolism and inflammation, and the triple-negative breast cancer in African American women
    Obesity has dramatically increased over the past fifty years. In the last decade, it has been noted that augmented body mass, metabolic abnormalities, and the relevant “obese”...
    Katarzyna Rygiel
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00066
    Viewed:1446
    Downloaded:55
    Open Access
    Original Article
    The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type
    Aim: Bromodomain and extra-terminal domain (BET) proteins are epigenetic readers that play a fundamental role in transcription regulation. Preclinical and early clinical evidence sustain BET targ...
    Chiara Tarantelli ... Francesco Bertoni
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00065
    Viewed:2501
    Downloaded:97
    Open Access
    Original Article
    Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
    Aim: Direct analytical comparison of two major drug-linkers in the antibody-drug conjugate (ADC) field was conducted. Methods: Four different analytical methods [AlogP calculation, reverse phase (RP) high-performance liquid chromatography (HPLC; RP-HPLC), size exclusion chromatography HPLC (SEC-HPLC), and differential scanning calorimetry (DSC)] were tested for this comparison....
    Tomohiro Fujii ... Yutaka Matsuda
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00064
    Viewed:2420
    Downloaded:154
    Open Access
    Original Article
    Alterations in the Ca2+ toolkit in oesophageal adenocarcinoma
    Aim: To investigate alterations in transcription of genes, encoding Ca2+ toolkit proteins, in oesophageal adenocarcinoma (OAC) and to assess associations between gene expression, tumor ...
    Alana L. Cutliffe ... John J. Mackrill
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00063
    Viewed:1908
    Downloaded:51
    Open Access
    Review
    Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
    The dismal prognosis of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) prompted recent advances in the field of therapeutic approaches beyond cytotoxic cancer therapy. In r...
    Stefano Cavalieri ... Laura D. Locati
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00062
    Viewed:2236
    Downloaded:95
    Open Access
    Review
    The clinical advances of proteolysis targeting chimeras in oncology
    Proteolysis targeting chimeras (PROTACs) are a class of small molecules designed to target proteins for degradation. Their novel and unique modes of action provide PROTACs with the potential for the...
    Hao Xie ... Jason B. Fleming
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00061
    Viewed:4089
    Downloaded:213
    Open Access
    Review
    Proteolysis-targeting chimeras and their implications in breast cancer
    Breast cancer (BC) is a highly heterogeneous neoplasm of the mammary tissue, causing the deaths of a large number of women worldwide. Nearly 70% and 20% of BC cases are estro...
    Angeles C. Tecalco-Cruz ... Alberto Rojas-Ochoa
    Published: December 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00060
    Viewed:2270
    Downloaded:85
    Open Access
    Review
    A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
    Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identifi...
    Giacomo Aimar ... Massimo Di Maio
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00056
    Viewed:1881
    Downloaded:79
    Open Access
    Review
    Targeted therapy of multiple myeloma
    Multiple myeloma (MM) is a malignant proliferative disease of monoclonal plasma cells (PCs) and is characterized by uncontrolled proliferation of PCs and excessive production of specific types of im...
    Shan Zhou, Renxi Wang
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00057
    Viewed:1640
    Downloaded:53
    Open Access
    Original Article
    Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center
    Aim: Since SARS-CoV-2 infection rapidly spread around the world, Italy has quickly become one of the most affected countries. Healthcare systems introduced strict infection control measures to ensu...
    Maristella Bungaro ... Silvia Novello
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00058
    Viewed:1264
    Downloaded:34
    Open Access
    Review
    Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer
    Adjuvant hormonal therapy is one of the most important treatments of hormone-receptor-positive breast cancer and includes selective estrogen receptor modulators, aromatase inhibitors, and luteinizin...
    Alfredo Rossi ... Marta Carlesimo
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00059
    Viewed:1545
    Downloaded:32
    Open Access
    Review
    Current options and future directions of systemic therapy for advanced biliary tract cancer
    Biliary tract cancers (BTCs) are aggressive tumors arising from different portions of the biliary tree and classified according to the anatomical location in intrahepatic (i) cholangiocarcinoma (CCA...
    Maria Giuseppina Prete ... Lorenza Rimassa
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00054
    Viewed:2748
    Downloaded:79
    Open Access
    Review
    Targeting protein kinase CK2 in the treatment of cholangiocarcinoma
    Cholangiocarcinoma (CCA) is a disease with a very poor prognosis and limited treatment options. Although targeted therapies directed towards specific mutations found in CCA are becoming available an...
    Padma-Sheela Jayaraman, Kevin Gaston
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00055
    Viewed:1963
    Downloaded:65
    Open Access
    Review
    A novel strategy for treating cancer: understanding the role of Ca2+ signaling from nociceptive TRP channels in regulating cancer progression
    Cancer is an aging-associated disease and caused by genomic instability that is driven by the accumulation of mutations and epimutations in the aging process. Although Ca2+ signaling, re...
    Wen-Li Hsu ... Etsuro Ito
    Published: October 31, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00053
    Viewed:2092
    Downloaded:67
    Open Access
    Review
    Role of estrogen receptor coregulators in endocrine resistant breast cancer
    Breast cancer (BC) is the most ubiquitous cancer in women. Approximately 70–80% of BC diagnoses are positive for estrogen receptor (ER) alpha (ERα). The steroid ho...
    Kristin A. Altwegg, Ratna K. Vadlamudi
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00052
    Viewed:3097
    Downloaded:97
    Open Access
    Review
    The promising potential of piperlongumine as an emerging therapeutics for cancer
    In spite of the immense advancement in the diagnostic and treatment modalities, cancer continues to be one of the leading causes of mortality across the globe, responsible for the death of around 10...
    Dey Parama ... Ajaikumar B. Kunnumakkara
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00049
    Viewed:3888
    Downloaded:151
    Open Access
    Review
    The evolving role and utility of off-label drug use in multiple myeloma
    The treatment landscape for multiple myeloma (MM) has dramatically changed over the last three decades, moving from no US Food and Drug Administration approvals and two active drug classes to over 1...
    James H Stoeckle ... Gareth J Morgan
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00050
    Viewed:2997
    Downloaded:43
    Open Access
    Review
    Does the gut microbiome environment influence response to systemic breast cancer treatment?
    The gut microbiome is a novel player in the pathogenesis and treatment of breast cancer. The term “microbiome” is used to describe the diverse community of micro-organisms exis...
    Eilidh Bruce ... Beatrix Elsberger
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00051
    Viewed:1905
    Downloaded:55
    Open Access
    Original Article
    The effect of iron on the expression levels of calcium related gene in cisplatin resistant epithelial ovarian cancer cells
    Aim: Anticancer drugs (chemotherapeutics) used in cancer treatment (chemotherapy) lead to drug resistance. This study was conducted to investigate the possible effect of iron on calcium homeostasis...
    Bahire Kucukkaya ... Leman Yalcintepe
    Published: August 30, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00048
    Viewed:1250
    Downloaded:39
    Open Access
    Review
    Targeting cytoskeletal phosphorylation in cancer
    Phosphorylation of cytoskeletal proteins regulates the dynamics of polymerization, stability, and disassembly of the different types of cytoskeletal polymers. These control the ability of cells to m...
    Clara Llorente-González ... Miguel Vicente-Manzanares
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00047
    Viewed:1707
    Downloaded:69
    Open Access
    Review
    Advances in the study of cancer metastasis and calcium signaling as potential therapeutic targets
    Metastasis is still the primary cause of cancer-related mortality. However, the underlying mechanisms of cancer metastasis are not yet fully understood. Currently, the epithelial-mesenchymal transit...
    Chaochu Cui ... Xianwei Wang
    Published: June 28, 2021 Explor Target Antitumor Ther. DOI: 10.37349/etat.2021.00046
    Abstract